Morphine and buprenorphine induce analgesia through some shared, but some distinct, signal transduction mechanisms. There is a novel supraspinal component to buprenorphine’s mechanism of analgesic action, providing the rationale for buprenorphine’s unique (pre)clinical profiles. Based on in vitro assays and some animal models, buprenorphine is commonly labeled a ‘partial agonist’, but in published clinical trials buprenorphine had full clinical analgesic efficacy compared to analgesics considered ‘full’ agonists in 25 of 26 studies. The results highlight the problems of inaccurate use of the terms ‘intrinsic activity’, ‘efficacy’, and ‘full-’ or ‘partial-’ agonist.
Robert B. Raffa, PhD
Dr. Raffa is Past Chair of the Department of Pharmaceutical Sciences at Temple University School of Pharmacy (Philadelphia) and Professor Emeritus (Temple University) and Adjunct Professor at the University of Arizona College of Pharmacy. He has a bachelor’s degree in Chemical Engineering (University of Delaware), bachelor’s degree in Physiological Psychology (University of Delaware), a master’s degree in Biomedical Engineering (Drexel University), master’s degree in Toxicology (Thomas Jefferson University) and a doctorate in Pharmacology (Temple University School of Medicine).
He was a Research Fellow and a Team Co-Leader for analgesics drug discovery at Johnson & Johnson and was pivotal in the elucidation of the mechanism of action and development of the analgesic drug tramadol (Ultram™). He is co-holder of several patents, including the combination of tramadol plus acetaminophen (Ultracet™). He has published over 300 papers in refereed journals, is the co-author or editor of several books on pharmacology, chemotherapy-induced adverse effects, and thermodynamics, and pharmacology teaching texts. He is a Co-Editor of the Journal of Clinical Pharmacy and Therapeutics.
He is a past president of the Mid-Atlantic Pharmacology Society and is the recipient of research and teaching awards. He maintains active research collaborations and lectures and consults worldwide on analgesics and analgesic combinations.
Buprenorphine for Pain: Pharmacology and Clinical Attributes
Wednesday, April 19, 2017
6:30-7:00pm Registration and Light Buffet Dinner
Continuing Medical Education
This event is eligible for AMA PRA Category 2 Credit(s)™ where physicians may self claim one (l) AMA PRA Category 2 Credit for each 60-minute hour engaged in the learning activity. Individual physicians may claim AMA PRA Category 2 Credits for learning experiences that have improved the care they provide their patients and may be earned for activities physicians have undertaken on their own that should be beneficial to their practice.
- Participants will learn how the basic pharmacology of buprenorphine translates into its therapeutic and safety clinical characteristics.
- Participants will learn how the inappropriate or misuse of the data and pharmacologic terminology impairs the understanding and use of this “unique” analgesic.
Drexel University College of Medicine
Geary Auditorium A – New College Building, 1st Floor
SE Corner of 15th and Vine Streets, Philadelphia, PA
Parking is available across the street from the auditorium and is also available in the Gateway parking lot behind Magee Rehabilitation Hospital and costs $5.00 after 5:00pm